Zobrazeno 1 - 10 of 185 pro vyhledávání: '"Segura PP"'
1
Akademický článek
Indicators to evaluate quality of care in head and neck cancer in Spain.
Autor: Hernández JJC; Departamento de Medicina, Universidad de Salamanca, Consejero Emérito de la Fundación ECO, Campus Universitario Miguel de Unamuno s/n, 37007, Salamanca, Spain. jjcruz@usal.es.; Fundación ECO, Madrid, Spain. jjcruz@usal.es., Arrula VA; Servicio de Oncología Médica, Hospital Universitario Basurto, Bilbao, Spain., Álvarez YE; Fundación ECO, Madrid, Spain.; Servicio de Oncología Médica, Hospital General Universitario Gregorio Marañón, Madrid, Spain., Castaño AG; Servicio de Oncología Médica, Hospital Universitario Marqués de Valdecilla, Santander, Spain., de Castro JJG; Servicio de Oncología Médica, Hospital Clínic de Barcelona, Barcelona, Spain., Docampo LI; Servicio de Oncología Médica, Hospital 12 de Octubre, Madrid, Spain., Sorrosal JL; Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Saragossa, Spain., Segura PP; Fundación ECO, Madrid, Spain.; Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain., Domínguez AR; Fundación ECO, Madrid, Spain.; Servicio de Oncología Médica, Hospital Regional Universitario de Málaga, Málaga, Spain., Campos-Lucas FJ; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain., Rodríguez IS; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain., Bessa M; Fundación ECO, Madrid, Spain., Gratal P; Fundación ECO, Madrid, Spain., Caballero-Martínez F; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain., Martín DM; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain., Antón-Rodríguez C; Facultad de Medicina, Universidad Francisco de Vitoria, Madrid, Spain., López R; Fundación ECO, Madrid, Spain.; Servicio de Oncología Médica, Hospital Clínico Universitario e Instituto de Investigación Sanitaria (IDIS) de Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.
Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 May; Vol. 26 (5), pp. 1089-1097. Date of Electronic Publication: 2023 Oct 17.
Zobrazit plný text záznamu
2
Akademický článek
SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).
Autor: Segura PP; Medical Oncology Department, Hospital Clínico San Carlos, IdISCC, Madrid, Spain., Quintela NV; Medical Oncology Department, Catalan Institute of Oncology, Barcelona, Spain.; Preclinical and Experimental Research in Thoracic Tumors (PReTT) Group, Oncobell Program, IDIBELL, L'Hospitalet, Barcelona, Spain., García MM; Medical Oncology Department, Hospital del Mar, Barcelona, Spain.; Cancer Research Program, Hospital del Mar Research Institute, Barcelona, Spain., Del Barco Berrón S; Medical Oncology Department, Unidad Cáncer de Mama y Tumores Cerebrales, Instituto Catalán de Oncologia, Hospital Universitario Doctor Josep Trueta, Girona, Spain., Sarrió RG; Medical Oncology Department. Hospital, Univeristari i Politècnic La Fe, Valencia, Spain., Gómez JG; Medical Oncology Department, Complejo Hospitalario Universitario de Orense, Orense, Spain., Castaño AG; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Martín LMN; Medical Oncology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain., Rubio OG; Medical Oncology Department, Hospital de Sant Pau i La Santa Creu, Barcelona, Spain., Losada EP; Medical Oncology Department, Hospital Clinic and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain. epineda@clinic.cat.
Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2023 Sep; Vol. 25 (9), pp. 2634-2646. Date of Electronic Publication: 2023 Aug 04.
Zobrazit plný text záznamu
3
Akademický článek
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Autor: Psyrri A; Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, Athens, Greece. Electronic address: Psyrri237@yahoo.com., Fayette J; Centre de Lutte Contre le Cancer Léon Bérard, Lyon-I University, Lyon, France., Harrington K; Division of Radiotherapy and Imaging, The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, London, UK., Gillison M; Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA., Ahn MJ; Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea., Takahashi S; Department of Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Weiss J; Division of Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, USA., Machiels JP; Department of Medical Oncology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels; Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain (UCLouvain), Brussels, Belgium., Baxi S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA., Vasilyev A; Department of General Physiology, Saint Petersburg State University, Saint Petersburg., Karpenko A; Department of Oncology, Leningrad Regional Oncology Dispensary, Saint Petersburg., Dvorkin M; Budgetary Institution of Healthcare, Omsk Regional Oncology Dispensary, Omsk, Russian Federation., Hsieh CY; Division of Hematology & Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung City, Taiwan., Thungappa SC; Department of Medical Oncology, Healthcare Global Enterprises Limited, Bengaluru, Karnataka, India., Segura PP; Servicio de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain., Vynnychenko I; Sumy Regional Clinical Oncology Dispensary, Sumy State University, Sumy, Ukraine., Haddad R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., Kasper S; Department of Medical Oncology, West German Cancer Center, University Hospital, Essen., Mauz PS; Department of Otolaryngology, Head and Neck Surgery, University of Tübingen, Tübingen, Germany., Baker V; Oncology R&D, Late-Stage Development, AstraZeneca, Cambridge, UK., He P; Statistics, AstraZeneca, Gaithersburg, USA., Evans B; Statistics, AstraZeneca, Gaithersburg, USA., Wildsmith S; Oncology R&D, Late-Stage Development, AstraZeneca, Cambridge, UK., Olsson RF; Oncology R&D, Late-Stage Development, AstraZeneca, Gothenburg, Sweden., Yovine A; Oncology R&D, Late-Stage Development, AstraZeneca, Cambridge, UK., Kurland JF; Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg., Morsli N; Oncology R&D, Late-Stage Development, AstraZeneca, Cambridge, UK., Seiwert TY; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA. Electronic address: tseiwert@jhmi.edu.
Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2023 Mar; Vol. 34 (3), pp. 262-274. Date of Electronic Publication: 2022 Dec 16.
Zobrazit plný text záznamu
4
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Autor: Meeks, HD, Song, H, Michailidou, K, Bolla, MK, Dennis, J, Wang, Q, Barrowdale, D, Frost, D, McGuffog, L, Ellis, S, Feng, B, Buys, SS, Hopper, JL, Southey, MC, Tesoriero, A, James, PA, Bruinsma, F, Campbell, IG, Broeks, A, Schmidt, MK, Hogervorst, FBL, Beckman, MW, Fasching, PA, Fletcher, O, Johnson, N, Sawyer, EJ, Riboli, E, Banerjee, S, Menon, U, Tomlinson, I, Burwinkel, B, Hamann, U, Marme, F, Rudolph, A, Janavicius, R, Tihomirova, L, Tung, N, Garber, J, Cramer, D, Terry, KL, Poole, EM, Tworoger, SS, Dorfling, CM, Van Rensburg, EJ, Godwin, AK, Guénel, P, Truong, T, Stoppa-Lyonnet, D, Damiola, F, Mazoyer, S, Sinilnikova, OM, Isaacs, C, Maugard, C, Bojesen, SE, Flyger, H, Gerdes, AM, Hansen, TVO, Jensen, A, Kjaer, SK, Hogdall, C, Hogdall, E, Pedersen, IS, Thomassen, M, Benitez, J, González-Neira, A, Osorio, A, Hoya, MDL, Segura, PP, Diez, O, Lazaro, C, Brunet, J, Anton-Culver, H, Eunjung, L, John, EM, Neuhausen, SL, Ding, YC, Castillo, D, Weitzel, JN, Ganz, PA, Nussbaum, RL, Chan, SB, Karlan, BY, Lester, J, Wu, A
Publikováno v: Meeks, HD; Song, H; Michailidou, K; Bolla, MK; Dennis, J; Wang, Q; et al.(2016). BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 108(2). doi: 10.1093/jnci/djv315. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/4352x4c7
© The Author 2015. Published by Oxford University Press. All rights reserved. Background: The K3326X variant in BRCA2 (BRCA2∗c.9976A>T p.Lys3326∗rs11571833) has been found to be associated with small increased risks of breast cancer. However, it
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::2e257deb42325fa5d996bf3be6cc8279
http://www.escholarship.org/uc/item/4352x4c7
Zobrazit plný text záznamu
5
Akademický článek
Drug delivery in leptomeningeal disease: Navigating barriers and beyond.
Autor: Arshad, Numair1 (AUTHOR), Biswas, Nupur1,2 (AUTHOR) nupur@rhenix.org, Gill, Jaya2 (AUTHOR), Kesari, Santosh3 (AUTHOR), Ashili, Shashaanka2 (AUTHOR)
Publikováno v: Drug Delivery. Dec2024, Vol. 31 Issue 1, p1-11. 11p.
Zobrazit plný text záznamu
6
Akademický článek
High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.
Autor: Castellón Rubio VE; Medical Oncology Department, Hospital Universitario Torrecárdenas, C/Hermandad de Donantes de Sangre, 04009 Almería, Spain; Cancer & Thrombosis Working Group, Spanish Society of Medical Oncology (SEOM), C/de Velázquez, 7, 28001 Madrid, Spain. Electronic address: victo_eu@yahoo.es., Segura PP; Cancer & Thrombosis Working Group, Spanish Society of Medical Oncology (SEOM), C/de Velázquez, 7, 28001 Madrid, Spain; Medical Oncology Department, Hospital Clínico San Carlos, Calle del Prof Martín Lagos, s/n, 28040 Madrid, Spain., Muñoz A; Cancer & Thrombosis Working Group, Spanish Society of Medical Oncology (SEOM), C/de Velázquez, 7, 28001 Madrid, Spain; Medical Oncology Department, Hospital General Universitario Gregorio Marañón, C/Doctor Esquerdo, 46, 28007 Madrid, Spain., Farré AL; Medicine Department, School of Medicine, Plaza Ramón y Cajal, SN, Universidad Complutense de Madrid, 28040 Madrid, Spain., Ruiz LC; Medical Oncology Department, Hospital Universitario Torrecárdenas, C/Hermandad de Donantes de Sangre, 04009 Almería, Spain., Lorente JA; Legal Medicine Department, School of Medicine, Av. Investigación, 11-PTS., Universidad de Granada, 18016 Granada, Spain.
Publikováno v: Thrombosis research [Thromb Res] 2020 Dec; Vol. 196, pp. 349-354. Date of Electronic Publication: 2020 Sep 16.
Zobrazit plný text záznamu
8
Hereditary pancreatic cancer: molecular bases and their application in diagnosis and clinical management. A guideline of the TTD group
Autor: Segura, PP, Ponce, CG, Cajal, TRY, Blanch, RS, Aranda, E
Publikováno v: Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Pancreatic carcinoma (PC) represents the fourth leading cause of cancer death in Spain with a death rate of 2,400 males and 2,000 females per year. Poor outcome related to its silent nature and the lack of reliable secondary prevention measures trans
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::40ba8304bc9ac6f701c56b5602d314fc
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=11159
Zobrazit plný text záznamu
9
TTD consensus document on the diagnosis and management of hereditary colorectal cancer
Autor: Segura, PP, Alonso, CG, Cajal, TRY, Blanch, RS, Aranda, E
Publikováno v: Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Colorectal cancer is the first cause of cancer in occidental countries if we consider both male and females tumours. In Spain, 26,000 new cases are diagnosed every year. The possibilities of cure are higher if the tumour is diagnosed early. One of th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::cd810325f454a63a6839f4994269254e
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=12746
Zobrazit plný text záznamu
10
Akademický článek
Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.
Autor: Shen, Yating1,2 (AUTHOR), Thng, Dexter Kai Hao1,2 (AUTHOR), Wong, Andrea Li Ann2,3 (AUTHOR), Toh, Tan Boon1,4 (AUTHOR) lsittb@nus.edu.sg
Publikováno v: Experimental Hematology & Oncology. 4/13/2024, Vol. 13 Issue 1, p1-32. 32p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje